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Abstract Helicobacter pylori is responsible for worldwide
chronic bacterial infection in humans affecting approximately
half of the world’s population. H. pylori is associated with
significant morbidity and mortality including gastric cancer.
The infection has both direct and indirect impacts on econom-
ic and overall well-being of patients; hence, there is a great
need for diagnostic markers that could be used in the devel-
opment of diagnostic kits. Here, we briefly review general
aspects of H. pylori infection and the diagnostic biomarkers
used in laboratory tests today with a focus on the potential role
of microfluidic systems in future immunodiagnosis platforms.
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Introduction
Helicobacter pylori infection is caused by a gram-negative
organism that colonizes the mucous layers and the apical sur-
face of human gastric epithelial cells (Alam et al. 2012;
Khalilpour et al. 2014a). More than 90 % of population in
developing and Eastern countries and half of the world popu-
lation have been affected with H. pylori infection (Chan et al.
2006a; Malaty 2007a). The prevalence rate of infection during
the first decade and by the sixth decade of life in industrialized
countries (West Europe and North America) is approximately
10 and 60 %, respectively. In nonindustrialized countries
(Africa, South America, Middle, and Far East), infection often
occurs during childhood by intrafamilial transmission with the
prevalence rate of 60–80 % that slightly increases with age. In
contrast, in developed countries, the annual prevalence of ac-
quisition of H. pylori infection is much lower (∼1 %) and is
estimated to be 30–40 % during adulthood (Rahim 2004).
H. pylori is related to peptic ulcer diseases (PUDs) such as,
duodenal ulcer (DU) and gastric ulcer (GU), gastric cancer
(GC), atrophic gastritis, and mucosa-associated lymphoid tis-
sue lymphoma (MALT) (Fig. 1a) (Kusters et al. 2006;
Lydyard et al. 2010). H. pylori infection may damage the
tissue in five different ways. First, damage is caused by am-
monium ions resulting from the urease activity and the pro-
duction of phospholipase and vacuolating cytotoxin, which
participate in the formation of a poor quality mucus layer.
Second, gastric physiology is altered by enhanced acid produc-
tion; the gastric cell dynamics are affected by interference in
normal cell signaling events caused by the introduction of the
CagA protein and peptidoglycan from Helicobacter. Third, re-
lease of free radicals from the granulocytes causes the damage.
Fourth, autoantibodies are induced byHelicobacter and kill acid-
secreting parietal cells. Lastly, the infection can alter the balance
of cell division and apoptosis (Fig. 1b) (Eslick 2006; Lydyard
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et al. 2010). Although H. pylori is related to serious dis-
eases, only a fraction of infected people will develop
gastroduodenal disease during their lifetime as limited
strains of H. pylori are highly pathogenic. In general,
the development of chronic gastritis depends on the vir-
ulence of the H. pylori strain, host susceptibility, and
environmental cofactors such as smoking and diet.
The major challenge in regard to treating diseases related to
H. pylori infection is to understand the pathogenesis of the
disease so that patients with a high risk of developing cancer
can be recognized and the disease can be prevented or treated
in the early stages. A variety of H. pylori antigens such as
UreA, UreB, CagA, VacA, FlaA, FlaB, and HspB have been
reported to elicit strong humoral immune responses, thus
Fig. 1 General scheme of infection withHelicobacter pylori. aA picture
ofH. pylori (i), the location of the organisms in the human stomach (ii), a
picture of the microscopic location ofH. pylori in the mucus layer and on
the surface epithelial cells (iii), and the location of a duodenal and gastric
ulcer (iv). b Mechanisms of pathogenesis of H. pylori. Reprinted with
permission from Lydyard et al. (2010)
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making them potential candidates as biomarkers associated with
H. pylori infection (Portal-Celhay and Perez-Perez 2006). A new
range of markers have been made into commercial diagnostic
kits and provide better efficiency in terms of accuracy and cost.
Currently, the approved diagnosing systems for H. pylori infec-
tion are often based on serological diagnosis or polymerase chain
reaction (PCR). Diagnostic kits that utilize stool antigens and
carbon-labeled urease breath tests have opened new options for
diagnosing activeH. pylori infections, however, most of them are
expensive and time consuming (Vaira and Vakil 2001).
This mini-review provides an overview of currently used
biomarkers and highlights the potential biomarkers related to
H. pylori infection. It also explores different immunoassays
regarding the detection of anti-H. pylori and outlines future
directions for the field.
Biomarkers
Biomarkers play major roles in molecular medicine in the
identification, validation, diagnosis, and prevention of dis-
ease. Biomarkers can reflect biological activities that are rele-
vant to disease and provide valuable information that may be
useful diagnostically and therapeutically. There are various
protein detection techniques that have been applied in
biomarker discovery. Sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) and Western
blotting are the most basic and traditional techniques
used for separation of macromolecules. Currently, these
techniques have been combined with high-throughput
techniques. Different experimental methods, such as
two-dimensional electrophoresis (2-DE), OFFGEL elec-
trophoresis, high-performance liquid chromatography
(HPLC), bioinformatics software, and mass spectrometry
(MS)-based high-throughput proteomics have been
employed for the discovery of essential proteins. A va-
riety of H. pylori antigens were identified using 2-DE
and mass spectrometry to elicit strong humoral immune
responses making them potential candidates for bio-
markers (Portal-Celhay and Perez-Perez 2006). The ma-
jority of studies have focused on the urease enzyme,
VacA, heat shock protein, and outer membrane protein
in order to quickly produce a diagnostic kit for the
diagnosis of H. pylori infection (Michetti et al. 1999).
Several clinical studies have suggested the application
of multiple antigens with high sensitivity and specificity
as an efficient combination for detecting H. pylori in-
fection (Manes et al. 2005; Pelerito et al. 2006).
Virulence factors
Virulence factors are frequently responsible for causing dis-
ease in a host because they inhibit certain biological functions.
Several virulence-associated genes of H. pylori have been re-
ported to play a major role in the pathogenesis of H. pylori.
Previous researches have focused on the urease enzymes,
CagA, VacA, FlaA, HspB, FlaB, and outer membrane proteins
in order to quickly produce a diagnostic kit for recognition of
H. pylori infection (Cremonini et al. 2004; Khalilpour et al.
2013; Schumann et al. 2006; Zheng et al. 2002). Although
some bacterial factors such as the heat shock protein, H. pylori
adhesin (HpaA), and flagella have also been identified as path-
ogenic determinants, understanding the function of H. pylori
cellular components in the pathogenesis of gastric disorders
requires further investigation (Park et al. 2006). In addition, a
few unidentified antigenic bands such as 18, 39.5, 33, and
34 kDa have been reported to be of good diagnostic value
(Andersen and Espersen 1992; Galmiche et al. 2000; Keenan
et al. 2000). For instance, Lin et al. (2007) detected seven pro-
teins in duodenal ulcer and gastric cancer serum samples with
relative molecular masses of 53 kDa (flagellin A), 53 kDa (fla-
gellin B), 67 kDa (molecular chaperone DnaK), 61 kDa (urease
β subunit), 74 kDa (flagellar hook-associated protein (FliD)),
76 kDa (flagellar hook protein), and 51 kDa (serine protease
(HtrA)) (Lin et al. 2007). Khalilpour et al. identified four
H. pylori infection markers including UreG, UreB, CagI, and
pyrroline-S-carboxylate dehydrogenase using off-gel and mass
spectrometry with high sensitivity and specificity (Fig. 2). Out
of the four H. pylori infection markers identified by Khalilpour
et al., UreG, CagI, and pyroline-S-carboxylate dehydrogenase
were reported for the first time (Khalilpour et al. 2014a;
Khalilpour et al. 2012; Khalilpour et al. 2013; Noordin et al.
2013).
After infection of the gastric or duodenal cells with
H. pylori, a number of things occur in the tissue. First, the
bacteria must penetrate the mucus layer and attach to the sur-
face of the epitheliums (Fig. 3). Several proteins that are in-
volved in this process also play a role in causing damage to the
host’s stomach. In some, but not all strains of H. pylori, the
protein called cytotoxin-associated gene A (CagA) is
expressed. This protein is related to the increased virulence
and risk of gastric carcinoma. CagA is encoded by a gene
placed in the Cag pathogenicity island (Cag PAI), which is
found in more than 90 % of H. pylori isolated in Eastern
countries and almost 60 % in Western countries (Chan et al.
2006b). The CagPAI is 40 kb in size and a complex of Cag
genes including CagI, CagE, CagL, CagH, and CagM, which
are a major virulence factor of H. pylori (Chan et al. 2006a;
Cui and Shao 2007).H. pylorimakes this protein via a type IV
secretion system and physically injects it into the mucosal
cells using its pilus (Fleming et al. 2009; Peek et al. 2010).
Vacuolating cytotoxin gene A (VacA) is another virulence
factor that is produced during H. pylori infection. A unique
exotoxin of H. pylori can cause vacuolation, disruption of
endo-lysosomal activity, apoptosis in gastric cells, pore for-
mation, and immunomodulation (Yan et al. 2005). A distinct
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allelic variant in two different parts of VacA has been
expressed. The presence of alleles s1a, s1b, and s2 and the
middle region (m) as the alleles m1 or m2 might lead to N-
terminal signal region (s). The different structure of VacA has
been related to the variations in the cytotoxin production as
well as the clinical effects of the H. pylori infection (Faundez
et al. 2002). The VacA protein is released outside of the
H. pylori where it binds to the outer surface of a stom-
ach cell and induces the vacuoles inside. The VacA
protein also inserts itself into the mitochondrial mem-
brane and induces apoptosis partly by forming pores
in the mitochondrial membrane. This cellular destruction
alerts the immune system to the fact that there is some-
thing occurring in the interior of the stomach.
Fig. 2 Schematic of identification of antigenic proteins of H. pylori. a
Gel profile (12%SDS-PAGE) of OFFGEL fractions of antigens using the
3100 OFFGEL High Res Kit, pH 3–10. b Representative profile of IgG
immunoblot of H. pylori antigen incubated with patient (S+) and control
serum sample (S−). c Mass spectrometric identification of antigenic
proteins of H. pylori. Reprinted with permission from Khalilpour et al.
(2013)
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Cytokines, produced by the injured cells send signals to
the immune system, leading to tissue infiltration of im-
mune cells.
Diagnosis of H. pylori infection
A number of tests with varying accuracy and sensitivity have
been developed to diagnose H. pylori infection. These tests
could be separated into invasive and noninvasive approaches,
depending on whether an endoscopy is needed. The choice of
test depends on factors such as the clinical situation, availabil-
ity, cost, pretest probability of infection, prevalence of infec-
tion in the population, the use of antibiotics that may affect test
results, etc. An invasive test is usually employed for children
and anyone with symptoms that indicate a cause for serious
concern (Hammett and Evans 1999; Mones et al. 2005). In an
adult, conditions such as advanced age, anemia, persistent
vomiting, a long history of symptoms, persistent weight loss
or lack of appetite, gastrointestinal bleeding, or severe stom-
ach pain that indicates an ulcer with complications might war-
rant this thorough examination (Fleming et al. 2009). This
type of test not only diagnoses the amount of damage in the
stomach but also allows the clinician to directly sample the
tissue to test it for the presence of the H. pylori organism.
Noninvasive tests can identify H. pylori in a sample, but do
not reveal the amount of tissue damage (Fleming et al. 2009;
Sugimoto et al. 2009).
Invasive tests
Histopathology staining remains one of the best methods for
detecting H. pylori infection, and together with visual obser-
vation by endoscopy, it provides important information based
on the pathological condition of the stomach (Makristathis
et al. 2004). However, endoscopy is expensive, unpleasant
for patients, and requires highly specialized operator to per-
form the test. In some cases, endoscopy is too costly to be used
as a routine diagnostic test for gastric patients. In addition,
sampling error may occur and cause false-negative results
(Mitchell and Megraud 2002) that can lead to inaccurate di-
agnosis. Bacterial culture is one of the options for detecting
the presence ofH. pylori. Successful culture of theH. pylori is
the gold standard for diagnosis. One of the advantages of
culture diagnosis is the antibiotic susceptibility test which
can be performed in cases of antibiotic resistance (Wadstrom
et al. 1994). However, the media used for culturingH. pylori is
costly, coupled with special conditions for maintenance, and
the length of time necessary to obtain a result is slow com-
pared to other methods (Perez-Perez 2000). The rapid urease
test (RUT) is used to detect the H. pylori urease enzyme in
gastric cells. A small biopsy sample is placed in a test vial
containing the rapid urease test solution and incubated over-
night at 37 °C. The sample is then observed for a change in
color from yellow to pink which indicates a positive result
(Yousfi et al. 1996). There are several versions of this test that
are quite sensitive and specific for H. pylori, but they vary in
the amount of time needed to get a result. This method is the
most time-efficient and is affordable for use as a routine diag-
nostic procedure (Fleming et al. 2009).
PCR is the most commonly used molecular technique for
the diagnosis of H. pylori, even though it has not been stan-
dardized (Brooks et al. 2004; Monteiro et al. 2001a). No at-
tempts have been made so far to standardize either the sample
preparation process or the PCR amplification itself.
Laboratories use different Bin-house^methods that often have
varying sensitivity and reliability. The PCR has been per-
formed successfully to identifyH. pyloriDNA in gastric tissue
by amplifying antigenic genes such as the urease gene,
adhesin genes, and 16S rRNA gene. The highly specific target
for PCR diagnosis of H.pylori is the 16S rRNA gene. This
gene is a popular target confirmingH. pylori infection and has
been previously used to help reclassifying the organism.
Urease is another specific target for detecting H. pylori infec-
tion, and positive amplification of bacterium-specific DNA
can be considered as a direct evidence of the presence of the
pathogen (Tiwari et al. 2005). These genes are routinely ob-
tained from clinical samples such as blood, biopsy tissues,
feces, saliva, whole blood, and cultures for diagnostic pur-
poses (Brooks et al. 2004; Chisholm and Owen 2008; Kim
Fig. 3 Using clever biochemical
strategy H. pylori liquefies
stomach mucin barrier by
increasing the pH of its
surroundings to cross over to the
epithelial cells and establish
colonies, attack surface cells, and
form ulcers. Reprinted with
permission from Deretsky (2015)
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et al. 2000; Monteiro et al. 2001b). However, the specificity
and sensitivity of the diagnosis varies, according to different
sample preparations and various laboratory conditions
(Sugimoto et al. 2009). Monoplex, multiplex, and nested
PCR methods are useful for specially identifying H. pylori
in biological samples. Real-time quantitative (Q) PCR tech-
nique is a more developed technique compared to the other
conventional methods for H. pylori clinical diagnosis.
However, this technique requires endoscopy to obtain biopsy
samples. Many primer sets have been reported for targeting
H. pylori, most of which are targeted at the small subunit RNA
nucleotide sequence that is highly conserved and contains
species-specific regions (He et al. 2002). Other reported prim-
er sets target the highly repetitive DNA sequences UreA,
UreB, UreC, and VacA (He et al. 2002).
Noninvasive tests
An interesting test to detect H. pylori is the urea breath test.
This method is the preferred noninvasive choice for H. pylori
diagnosis before and after treatment. The urea breath test uses
the fact that H. pylori yields urease, an enzyme that metabo-
lizes urea into ammonia and carbon dioxide (CO2). For this
test, patients swallow a tablet that contains a small amount of
13C-labeled urea (Abdullahi et al. 2008; Fleming et al. 2009).
13C is a nonradioactive form of carbon that is slightly heavier
than normal carbon. The 13-CO2 is absorbed through the
stomach lining and transported to the circulatory system.
After 20 min, a breath sample is analyzed by a machine.
Patients without H. pylori infections will produce little or no
13-CO2, and the urea will be eliminated in the feces and urine.
The urea breath test is known as the Bgold standard^ for in
vivo detection of H. pylori infection and is also a good means
of evaluating whether a course of H. pylori therapy has suc-
cessfully eradicated the organism. However, this test may be
less reliable for children due to the lower production of CO2 in
children compared to adults (Boncristiano et al. 2003; Wang
et al. 2013).
The fecal antigen test is a noninvasive method of diagnosis
of H. pylori antigens in the feces of patients suspected of
having an active H. pylori infection (Andrews et al. 2003).
Studies have proved the accuracy of the fecal antigen test
named the H. pylori stool antigen (HpSA) test for detection
ofH. pylori infection (Iranikhah et al. 2013). The test is highly
sensitive and precise and is especially good for diagnosing
infection in children who are unable to perform a UBT.
Nevertheless, some studies have shown increased false-
negative results for the stool antigen test during proton pump
inhibitor (PPI) treatment. PPIs such as omeprazole or
lansoprazole are a group of drugs that work by reducing the
amount of stomach acid made by glands in the lining of stom-
ach. They are the most potent inhibitors of acid secretion
available (Fleming et al. 2009; Kodama et al. 2012).
Infection with H. pylori excites a strong immune response
that results in the production of antibodies. Antibodies specific
to H. pylori in serum, whole blood, saliva, and stool can be
detected using serological methods like enzyme-linked immu-
nosorbent assay (ELISA) and Western blotting (Alkout et al.
1997; Faulde et al. 1991; Kimmel et al. 2000). A positive
antibody test, along with dyspeptic symptoms may be
convincible enough for a physician to prescribe antibiotic
therapy to eradicate the H. pylori infection. However, a con-
cern regarding blood tests is the remain of antibodies in the
circulatory system for months or years after the elimination of
infection which may result in misdiagnosis and improper
treatment due to false-positive serological test result.
In general, invasive tests are more reliable than noninvasive
tests for diagnosing an infection, as noninvasive tests some-
times fail to detect the organism in an infected person (false-
negative) or incorrectly diagnose an uninfected person (false-
positive) (Fleming et al. 2009).
Miniaturized and point of care diagnostic tools
The conventional invasive and noninvasive methods such as
PCR, serological tests, and ELISA have some restrictions for
their applications as they require long processing times, high
quantity of costly reagents, and equipment. Thus, these pro-
cesses are centralized and samples should be collected and
transferred to a central lab to be processed (Bhattacharyya
and Klapperich 2007; Eteshola and Leckband 2001). To ad-
dress these limitations, miniaturized diagnostic tools including
microfluidic-based systems have been developed. The smaller
length scales, in comparison with conventional systems, re-
duce the diffusion time of reagents and the required time for
assays. In addition, miniaturized systems require less reagents
and sample size in comparison with conventional tests (Riahi
et al. 2015). These miniaturized systems are also portable and
can easily be multiplexed for parallel detection of various
diseases. These characteristics make them ideal for designing
point of care (POC) diagnostic tools.
Lateral flow tests, also known as Immunochromatographic
assays, are simple, cheap, efficient, and easy to apply, which
have been widely employed for designing POC diagnostics. A
number of lateral assays have been developed for H. pylori
detection (Hujakka et al. 2003; Khalilpour et al. 2014b). Yang
and Seo (2008) compared the sensitivity and reliability of a
rapid lateral assay with conventional ELISA system for detec-
tion of stool antigen (HpSA). They did not observe any sig-
nificant difference between the two assays, while the lateral
one was 20 times faster. The key challenge associated with
lateral assays is their high background noise that can poten-
tially reduce their limit of detection. Thus, polymer-based
microfluidic systems which have a lower background noise
have recently drawn significant attention for designing POC
diagnostics (Gubala et al. 2011). Recent development of
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microfabrication technologies that has significantly reduced
the fabrication cost of polymer-based microfluidics has made
their commercialization more probable.
Liquid handling in microfluidic systems has normally been
achieved by the use of (1) centrifugal force, (2) electrical forces,
(3) surface tension, and (4) pressure. Among them, surface
tension-based systems can be autonomous and are excellent can-
didates for POC diagnostics (Safavieh and Juncker 2013;
Safavieh et al. 2015). In an example, Pereira et al. designed an
integratedmagnetic immunosensor coupledwith a gold electrode
for the detection of H. pylori-specific IgG antibodies (Fig. 4a).
Their results show the potential usefulness of their made-up
microbiochip for the early assessment of IgG antibodies to
H. pylori (Pereira et al. 2010). In another example, Gao et al.
designed an electrokinetically driven microfluidic platform for
detection of H. pylori (Gao et al. 2005; Safavieh and Juncker
2013). The assay took only 30min and the chips stayed active for
at least 10 days. Using a similar microfluidic immunoassay ap-
proach, Goa et al. also designed a simple electrokinetically con-
trolled immunoassay chip for diagnosis ofH. pylori. In this chip,
anH-shapedmicrochannel networkwas fabricated using PDMS.
Multibiomarker immobilization was done by adsorbing the bio-
markers onto a PDMS-coated glass slide with the aid of a
microfluidic network (Fig. 4b). The assay time was only
25 min (Gao et al. 2005; Kakaç et al. 2010; Lin et al. 2004).
Lin et al. (2004) also employed a pressure-driven microfluidic
platform for rapid detection of H. pylori. The system could pro-
vide accurate readings within 30 min, while the required solution
volumes were 100-fold less than conventional ELISA systems
(Fig. 4c). The same group also developed a heterogeneous
PDMS-based microfluidic immunoassay with antibody-
functionalized RLS nanoparticles described as labels for the de-
tection ofH. pylori. This approach has the same detection limit as
a conventional ELISA system, while it allows long-term preser-
vation (Fig. 4d) (Lin et al. 2005).
Miniaturized systems provide a strong tool for rapid diag-
nosis of H. pylori and possess superiority over conventional
systems in terms of processing time, required facilities, and
used reagents and samples. A key point in their widespread
utilization is the feasibility of extracting the data by users. The
systems that utilize calorimetric readouts are easy to use for
negative/positive results. However, these systems are not easy
to use for measuring the antigen concentration unless they are
paired with an image processing tool. This can be achieved by
utilization of smartphones which are widespread. Electrical-
based sensing platforms on the hand are easier for reporting
concentrations.
Commercial diagnostic kits
Two types of markers, namely DNA and protein markers, are
used in commercial diagnostic kits for diagnosing H. pylori
infection. The accuracy of these markers varies from test to
test and depends greatly on the type of sample and the type of
assay (Vaira and Vakil 2001). DNA markers are detected by
means of a PCR test and will give very sensitive results. A few
commercial DNA diagnostic kits are available for H. pylori,
but most tests are performed in specialized laboratories with
trained personnel (el-Zaatari et al. 1997).
Protein-based markers are popular for H. pylori detection,
as they are manufactured into cheap user-friendly forms, such
as immobilized strips. Besides that, protein-based diagnostic
kits are also available in ELISA and latex agglutination test
cards (Glassman et al. 1990). ELISA kits are the most sensi-
tive and specific test for diagnosis ofH. pylori infection; how-
ever, these tests are expensive and time consuming. Another
lab-based serological method is immunoblotting.
Immunoblotting is also performed as a lab-based serological
method. These assays detect anti-H. pylori antibodies in either
fecal, whole blood, serum, or urine (Glassman et al. 1990;
Miwa et al. 2001; Sasidharan and Uyub 2009; Simor et al.
1996; Zuniga-Noriega et al. 2006). Most of the commercial
antibody-based tests for detecting H. pylori infection use bac-
terial lysate or partially purified bacterial antigens. Only a few
recombinant antigen-based tests have recently been intro-
duced into the market. Due to higher level of sensitivity and
specificity, most commercial diagnostic assays apply a mix-
ture of antigenic extracts over a single antigen. However, the
names of antigens used in commercial kits are usually undis-
closed (Table 1) (Andersen and Espersen 1992; Glassman
et al. 1990; Manes et al. 2005; Pelerito et al. 2006; Simor
et al. 1996).
The cost of diagnostics is also one of the main factors for
developing rapid kits. To decrease the cost, several factors
should be monitored: (1) use the least expensive reagents, (2)
production cost for mass production, (3) miniaturization, and
(4) quality control. In addition, for clinical use of diagnostic
devices, environmental conditions, such as high temperatures
(35∼45 °C), humidity, insufficient water, and unreliable elec-
tricity are of importance (Lee et al. 2010).
Lateral flow tests, also called immunochromatographic as-
says, are simple, cheap, efficient, and easy to apply. They do
not require a reader device or expensive equipment, and they
can be performed by an untrained person (Hujakka et al. 2003;
Khalilpour et al. 2014b). Therefore, lateral flow tests are sim-
ple tools intended to detect the presence ofH. pylori antigenic
protein in sample without requiring for costly equipment.
Conclusions
Rapid diagnosis and treatment plays a major role in inhibiting
the spread ofH. pylori infection.Moreover, aberrant diagnosis
and treatment may lead to drug misuse subject to unpredict-
able side effects. There are many immunoassays that have
Appl Microbiol Biotechnol (2016) 100:4723–4734 4729
been developed for the diagnosis of anti-H. pylori class serum
antibodies (IgG/IgM/IgA) (Khalilpour et al. 2014a;
Khalilpour et al. 2013). The diagnosis of H. pylori infection
markers via serology is the easiest noninvasive method for
diagnosing an infection as it requires only a few drops of
blood from the finger and the results are available in less than
5 min. However, serological diagnosis is still not widely rec-
ognized because of the prevalence of H. pylori antibodies
posttreatment (Rosenstock et al. 2000). A new range of
markers have been made into commercial diagnostic kits
and provide better accuracy and cost-effectiveness.
Diagnostic kits that utilize stool antigens and carbon-labeled
urease breath tests (Manes et al. 2001a; Manes et al. 2001b)
have opened new options for diagnosing active H. pylori in-
fections (Vaira and Vakil 2001).H. pylori strains are known to
differ in their pathogenicity from country to country. This
phenomenon is also supported by a few published studies
stating that different strains from different countries
might differ genetically and thus might differ in patho-
genicity (Das and Paul 2007; Kusters et al. 2006;
Malaty 2007b; Robinson et al. 2007). The accuracy of
the diagnostic biomarkers varies from test to test, de-
pending greatly on type of sample and type of diagnos-
tic assay (Vaira and Vakil 2001). Many commercial
ELISA kits for serological diagnosis of H. pylori anti-
bodies have been considered to provide reliable results
when used in the Western countries (Meijer et al.
1997a). However, when these serological kits were test-
ed in Asian or middle east countries, the diagnostic
accuracy of these tests were found to be lower, such
as reports from Chinese (Leung et al. 1999) and
Japanese patient populations (Miwa et al. 2001). These
differences may be due to some reasons, such as cross-
reactivity to other intestinal bacteria which vary in
Fig. 4 Nano/microfluidic technologies for detection of H. pylori
infection. a Schematic of an integrated magnetic immunosensor
coupled with a gold electrode for the detection of H. pylori-specific IgG
antibodies. b Schematic of an immunoassay chip with an H-shaped
microchannel, a sequential steps of an automatic IA processes. c
H. pylori antigen detection using the PDMS microchannel ELISA. d
H. pylori antigen detection in PDMS microchannels with the RLS
nanoparticles as the readout for the heterogeneous immunoassay.
Reprinted with permission from Kakaç et al. (2010); Lin et al. (2005),;
Lin et al. (2004), and Pereira et al. (2010)
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different parts of the world, the presence of H. pylori strain
heterogeneity in different geographic areas (Ito et al. 1997),
and varying immunological responses to antigenic proteins of
H. pylori in different patient populations (Khanna et al. 1998).
A lot of money is being spent on purchasing diagnostic kits
which may not be suitable for patients in other countries and
may not be as sensitive as kits made from antigens using
locally isolated H. pylori (Khalilpour et al. 2013; Meijer
et al. 1997b).
Therefore, the development of lateral flow tests using
recombinant forms of antigenic proteins could hopefully
solve the limitation of H. pylori diagnostic kits
(Khalilpour et al. 2014a). Combination of potential di-
agnostic markers could be used as an ideal clinical
diagnostic reagent for diagnosis of H. pylori infection with
effective applications, globally (Khalilpour et al. 2013).
Nevertheless, identification of diagnostic biomarkers
for local usage is essential. Microfluidic systems for
clinical assays could also enable on-chip detection of
blood-associated infectious diseases in simple, mass-pro-
ducible, and thus, cheap setting (Chung et al. 2009).
Diagnosis of H. pylori infection could be enhanced by
modification of current detection methods related to
nano/microfluidics interface using lateral flow and diffu-
sion (Bhattacharyya and Klapperich 2007; Eteshola and
Leckband 2001; Morozov et al. 2007).
Future directions
H. pylori has been an increasing source of gastrointestinal
disorders in the world, and its proper diagnosis is of high
priority. Part of the research is focused on identifying bio-
markers that are specific and reliable for its detection. These
biomarkers have been detected in different sources including
serum and stool. Thus, it is expected that either new bio-
markers will be identified or existing markers will be better
characterized to facilitate the disease diagnosis. Another ac-
tive area of research is on developing tools for detecting these
markers in biomarkers. Current strategies for H. pylori detec-
tion are based on culture of biopsy samples or the use of
ELISA-based immunoassays. However, these systems are
not easy-to-use and require central facilities, which reduce
their success as point of care and rapid diagnostic tools.
Thus, there is an increasing need to create on-chip immuno-
assays. The existing technologies that have potential for fur-
ther development include lateral assays with high sensitivity
and low background noise. In addition, autonomous capillary-
driven microfluidic systems hold a great promise for develop-
ing highly sensitive assays. It is expected that along with the
future development of these technologies, novel diagnostic
tools for detection of H. pylori will emerge. In addition, the
rapid progress in the development of smartphones and flexible
electronics and their integration with lateral assays and
Table 1 List of common
commercial kits for diagnosis of
H. pylori infection
Test format Type of sample Type of antigen Sensitivity Specificity
ELISA kit Human stool Recombinant CagA
Recombinant VacA
Recombinant UreB
Recombinant 26KD
Not available Not available
Rapid qualitative
immunochromatographic
Human stool CagA, VacA, CagII,
CagC
95 % Not available
IgA ELISA assay Human serum
or plasma
Recombinant antigens Not available Not available
ELISA kit Human serum Recombinant CagA Not available Not available
IgA ELISA kit Human serum
or plasma
Recombinant CagA
Recombinant urease
90.0 % 95.0 %
IgG ELISA kit Human serum
or plasma
CagA (120KD) VacA
(87KD) urease
93.7 % 93.3 %
Rapid H. pylori antigen
test card
Human stool Not available Not available Not available
Immunochromatographic
rapid assay
Human stool Not available 94.0 % 96.7 %
IgG chemiluminescence
ELISA (CLIA)
Human serum
or plasma
Not available 99 % 97 %
IgA ELISA Human serum
or plasma
Not available Not available Not available
IgM chemiluminescence
ELISA
Human serum
or plasma
Not available Not available Not available
IgA ELISA kit Human serum
and plasma
Recombinant CagA Not available Not available
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microfluidic platforms will lead to the development of point of
care that utilizes optical and electrochemical systems.
Compliance with ethical standards This article does not contain any
studies with human participants or animals performed by any of the au-
thors.
Conflict of interest The authors declare that they have no conflict of
interest.
References
Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J,
Leonetti F, Severi C (2008) The eradication of Helicobacter pylori
is affected by body mass index (BMI). Obes Surg 18(11):1450–
1454. doi:10.1007/s11695-008-9477-z
Alam J, Maiti S, Ghosh P, De R, Chowdhury A, Das S, Macaden R,
Devarbhavi H, Ramamurthy T, Mukhopadhyay AK (2012)
Significant association of the dupA gene ofHelicobacter pyloriwith
duodenal ulcer development in a South-east Indian population. J
Med Microbiol 61(Pt 9):1295–1302. doi:10.1099/jmm.0.038398-0
Alkout AM, Blackwell CC, Weir DM, Poxton IR, Elton RA, Luman W,
Palmer K (1997) Isolation of a cell surface component of
Helicobacter pylori that binds H type 2, Lewis(a), and Lewis(b)
antigens. Gastroenterolo 112(4):1179–1187
Andersen LP, Espersen F (1992) Immunoglobulin G antibodies to
Helicobacter pylori in patients with dyspeptic symptoms investigat-
ed by the western immunoblot technique. J Clin Microbiol 30(7):
1743–1751
Andrews J, Marsden B, Brown D, Wong VS, Wood E, Kelsey M (2003)
Comparison of three stool antigen tests for Helicobacter pylori de-
tection. J Clin Pathol 56(10):769–771
Bhattacharyya A, Klapperich CM (2007) Design and testing of a dispos-
able microfluidic chemiluminescent immunoassay for disease bio-
markers in human serum samples. Biomed Microdevices 9(2):245–
251. doi:10.1007/s10544-006-9026-2
Boncristiano M, Paccani SR, Barone S, Ulivieri C, Patrussi L, Ilver D,
Amedei A, D’Elios MM, Telford JL, Baldari CT (2003) The
Helicobacter pylori vacuolating toxin inhibits T cell activation by
two independent mechanisms. J Exp Med 198(12):1887–1897. doi:
10.1084/Jem.20030621
BrooksHJ, AhmedD,McConnell MA, Barbezat GO (2004) Diagnosis of
Helicobacter pylori infection by polymerase chain reaction: is it
worth it? Diagn Microbiol Infect Dis 50(1):1–5. doi:10.1016/j.
diagmicrobio.2003.11.010
Chan CHKC, Chang JG, Chen SF, Wu MS, Lin JT, Chow LP (2006b)
Subcellular and functional proteomic analysis of the cellular re-
sponses induced by Helicobacter pylori. Mol Cell Proteomics
5(4):702–713
Chan CH, Ko CC, Chang JG, Chen SF, Wu MS, Lin JT, Chow LP
(2006a) Subcellular and functional proteomic analysis of the cellular
responses induced by Helicobacter pylori. Mol Cell Proteomics
5(4):702–713
Chisholm SA, Owen RJ (2008) Application of polymerase chain
reaction-based assays for rapid identification and antibiotic resis-
tance screening of Helicobacter pylori in gastric biopsies. Diagn
Microbiol Infect Dis 61(1):67–71. doi:10.1016/j.diagmicrobio.
2007.12.005
Chung S, Yun H, Kamm RD (2009) Nanointerstice-driven microflow.
Small 5(5):609–613. doi:10.1002/smll.200800748
Cremonini F, Gabrielli M, Gasbarrini G, Pola P, Gasbarrini A (2004) The
relationship between chronic H. pylori infection, CagA seropositiv-
ity and stroke: meta-analysis. Atherosclerosis 173(2):253–259. doi:
10.1016/j.atherosclerosis.2003.12.012
Cui LL, Shao SH (2007) The type IV secretion system encoded by the
cag PAI of Helicobacter pylori. Wei Sheng Wu Xue Bao = Acta
Microbiologica Sinica 47(4):743–745
Das JC, Paul N (2007) Epidemiology and pathophysiology of
Helicobacter pylori infection in children. Indian J Pediatr 74(3):
287–290
Deretsky Z (2015) Uncovering the secrets of ulcer-causing bacteria.
National Science Foundation, Virginia
Eslick GD (2006) Helicobacter pylori infection causes gastric cancer? A
review of the epidemiological, meta-analytic, and experimental ev-
idence. World J Gastroenterol:WJG 12(19):2991–2999
Eteshola E, Leckband D (2001) Development and characterization of an
ELISA assay in PDMS microfluidic channels. Sensors Actuators B
Chem 72(2):129–133
Faulde M, Putzker M, Mertes T, Sobe D (1991) Evaluation of an immu-
nofluorescence assay for specific detection of immunoglobulin G
antibodies directed against Helicobacter pylori, and antigenic
cross-reactivity between H. pylori and Campylobacter jejuni. J
Clin Microbiol 29(2):323–327
Faundez G, Troncoso M, Figueroa G (2002) cagA and vacA in strains of
Helicobacter pylori from ulcer and non-ulcerative dyspepsia pa-
tients. BMC Gastroenterol 2:20
Fleming SL, Alcamo IE, Heymann DL (2009) Helicobacter pylori.
Chelsea House, NY
GalmicheA, Rassow J, Doye A, Cagnol S, Chambard JC, Contamin S, de
Thillot V, Just I, Ricci V, Solcia E, Van Obberghen E, Boquet P
(2000) The N-terminal 34 kDa fragment of Helicobacter pylori
vacuolating cytotoxin targets mitochondria and induces cytochrome
c release. Embo J 19(23):6361–6370. doi:10.1093/emboj/19.23.
6361
Gao Y, Lin FY, Hu G, Sherman PM, Li D (2005) Development of a novel
electrokinetically drivenmicrofluidic immunoassay for the detection
of Helicobacter pylori. Anal Chim Acta 543(1):109–116
GlassmanMS,Dallal S, Berezin SH, BostwickHE,NewmanLJ, Perez-Perez
GI, Blaser MJ (1990) Helicobacter pylori-related gastroduodenal dis-
ease in children. Diagnostic utility of enzyme-linked immunosorbent
assay. Dig Dis Sci 35(8):993–997
Gubala V, Harris LF, Ricco AJ, Tan MX, Williams DE (2011) Point of
care diagnostics: status and future. Anal Chem 84(2):487–515
Hammett DC, Evans MF (1999) Functional (non-ulcer) dyspepsia and
Helicobacter pylori infection. To treat or not to treat? Can Fam
Physician 45:2323–2326
He Q, Wang JP, Osato M, Lachman LB (2002) Real-time quantitative
PCR for detection of Helicobacter pylori. J Clin Microbiol 40(10):
3720–3728
Hujakka H, Koistinen V, Kuronen I, Eerikainen P, Parviainen M,
Lundkvist A, Vaheri A, Vapalahti O, Narvanen A (2003)
Diagnostic rapid tests for acute hantavirus infections: specific tests
for Hantaan, Dobrava and Puumala viruses versus a hantavirus com-
bination test. J Virol Methods 108(1):117–122
Iranikhah A, Ghadir MR, Sarkeshikian S, Saneian H, Heiari A, Mahvari
M (2013) Stool antigen tests for the detection ofHelicobacter pylori
in children. Iran J Pediatr 23(2):138–142
Ito Y, Azuma T, Ito S, Miyaji H, Hirai M, Yamazaki Y, Sato F, Kato T,
Kohli Y, Kuriyama M (1997) Analysis and typing of the vacA gene
from cagA-positive strains of Helicobacter pylori isolated in Japan.
J Clin Microbiol 35(7):1710–1714
Kakaç S, Kosoy B, Li D, Pramuanjaroenkij A (2010)Microfluidics based
microsystems: fundamentals and applications. Springer, Dordrecht
Keenan J, Oliaro J, Domigan N, Potter H, Aitken G, Allardyce R, Roake J
(2000) Immune response to an 18-kilodalton outer membrane
4732 Appl Microbiol Biotechnol (2016) 100:4723–4734
antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine
candidate. Infect Immun 68(6):3337–3343
Khalilpour A, Osman S, Yunus MH, Santhanam A, Vellasamy N,
Noordin R (2014a) Helicobacter pylori recombinant UreG protein:
cloning, expression, and assessment of its seroreactivity. BMC Res
Notes 7:809. doi:10.1186/1756-0500-7-809
Khalilpour A, Sadjjadi SM, Moghadam ZK, Yunus MH, Zakaria
ND, Osman S, Noordin R (2014b) Lateral flow test using
Echinococcus granulosus native antigen B and comparison
of IgG and IgG4 dipsticks for detection of human cystic
echinococcosis. AmJTrop Med Hyg 91(5):994–999. doi:10.
4269/ajtmh.14-0170
Khalilpour A, Santhanam A, Wei LC, Mohammad A, Osman S, Noordin
R (2012) Helicobacter pylori proteins with diagnostic potential
identified using proteomic approach. Int J Infect Dis 16:E396–
E397. doi:10.1016/j.ijid.2012.05.529
Khalilpour A, Santhanam A, Wei LC, Saadatnia G, Velusamy N, Osman
S, Mohamad AM, Noordin R (2013) Antigenic proteins of
Helicobacter pylori of potential diagnostic value. Asian Pac J
Cancer Prev 14(3):1635–1642
Khanna B, Cutler A, Israel NR, PerryM, Lastovica A, Fields PI, Gold BD
(1998) Use caution with serologic testing for Helicobacter pylori
infection in children. J Infect Dis 178(2):460–465
Kim N, Lim SH, Lee KH, You JY, Kim JM, Lee NR, Jung HC, Song IS,
Kim CY (2000) Helicobacter pylori in dental plaque and saliva.
Korean J Intern Med 15(3):187–194
Kimmel B, Bosserhoff A, Frank R, Gross R, Goebel W, Beier D (2000)
Identification of immunodominant antigens from Helicobacter
pylori and evaluation of their reactivities with sera from patients
with different gastroduodenal pathologies. Infect Immun 68(2):
915–920
Kodama M, Murakami K, Okimoto T, Fukuda Y, Shimoyama T, Okuda
M, Kato C, Kobayashi I, Fujioka T (2012) Influence of proton pump
inhibitor treatment onHelicobacter pylori stool antigen test.World J
Gastroenterol 18(1):44–48. doi:10.3748/wjg.v18.i1.44
Kusters JG, van Vliet AH, Kuipers EJ (2006) Pathogenesis of
Helicobacter pylori infection. Clin Microbiol Rev 19(3):449–490.
doi:10.1128/CMR.00054-05
Lee WG, Kim YG, Chung BG, Demirci U, Khademhosseini A (2010)
Nano/microfluidics for diagnosis of infectious diseases in develop-
ing countries. Adv Drug Deliv Rev 62(4–5):449–457. doi:10.1016/
j.addr.2009.11.016
Leung WK, Ng EK, Chan FK, Chung SC, Sung JJ (1999) Evaluation of
three commercial enzyme-linked immunosorbent assay kits for di-
agnosis ofHelicobacter pylori in Chinese patients. Diagn Microbiol
Infect Dis 34(1):13–17
Lin FY, Sabri M, Alirezaie J, Li D, Sherman PM (2005) Development of a
nanoparticle-labeled microfluidic immunoassay for detection of
pathogenic microorganisms. Clin Diagn Lab Immunol 12(3):418–
425
Lin FY, Sabri M, Erickson D, Alirezaie J, Li D, Sherman PM (2004)
Development of a novel microfluidic immunoassay for the detection
of Helicobacter pylori infection. Analyst 129(9):823–828
Lin Y-F, Chen C-Y, Tsai M-H, WuM-S, Wang Y-C, Chuang EY, Lin J-T,
Yang P-C, Chow L-P (2007) Duodenal ulcer-related antigens from
Helicobacter pylori. Immunoproteome and protein microarray ap-
proaches. Mol Cell Proteomics 6(6):1018–1026
Lydyard PM, Cole MF, Holton J, Irving WL, Porakishvili N, Venkatesan
P, Ward KN (2010) Case studies in infectious disease, vol 16.
Garland Science, New York
Makristathis A, Hirschl AM, Lehours P, Megraud F (2004) Diagnosis of
Helicobacter pylori infection. Helicobacter 9(Suppl 1):7–14. doi:10.
1111/j.1083-4389.2004.00254.x
Malaty HM (2007a) Epidemiology ofHelicobacter pylori infection. Best
Pract Res Clin Gastroenterol 21:205–214
Malaty HM (2007b) Epidemiology ofHelicobacter pylori infection. Best
Pract Res Clin Gastroenterol 21(2):205–214. doi:10.1016/j.bpg.
2006.10.005
Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo MM, Giardullo N,
Todisco A, Lioniello M, Vaira D (2001a) Accuracy of stool antigen
test in posteradication assessment of Helicobacter pylori infection.
Dig Dis Sci 46(11):2440–2444
Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo MM, Giardullo N,
Todisco A, Lioniello M, Vaira D (2001b) Accuracy of the stool
antigen test in the diagnosis of Helicobacter pylori infection before
treatment and in patients on omeprazole therapy. Aliment Pharmacol
Ther 15(1):73–79
Manes G, Zanetti MV, PiccirilloMM, Lombardi G, BalzanoA, Pieramico
O (2005) Accuracy of a new monoclonal stool antigen test in post-
eradication assessment ofHelicobacter pylori infection: comparison
with the polyclonal stool antigen test and urea breath test. Dig Liver
Dis 37(10):751–755. doi:10.1016/j.dld.2005.03.012
Meijer BC, Thijs JC, Kleibeuker JH, van Zwet AA, Berrelkamp RJ
(1997a) Evaluation of eight enzyme immunoassays for detection
of immunoglobulin G against Helicobacter pylori. J Clin
Microbiol 35(1):292–294
Meijer BC, Thijs JC, Kleibeuker JH, van Zwet AA, Berrelkamp RJP
(1997b) Evaluation of eight enzyme immunoassays for detection
of immunogloblin G against Helicobacter pylori. J Clin Microbiol
35:292–294
Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D,
Herranz M, Saldinger PF, Corthesy-Theulaz I, Losonsky G, Nichols
R, Simon J, StolteM, Ackerman S,Monath TP, BlumAL (1999) Oral
immunization with urease and Escherichia coli heat-labile enterotoxin
is safe and immunogenic in Helicobacter pylori-infected adults.
Gastroenterology 116(4):804–812
Mitchell H, Megraud F (2002) Epidemiology and diagnosis of
Helicobacter pylori infection. Helicobacter 7(Suppl 1):8–16
Miwa H, Akamatsu S, Tachikawa T, Sogabe T, Ohtaka K, Nagahara A,
Sugiyama Y, Sato N (2001) On-site diagnosis of H. pylori infection
by urine. Diagn Microbiol Infect Dis 39(2):95–97
Mones J, Gisbert JP, Borda F, Dominguez-Munoz E (2005) Indications,
diagnostic tests and Helicobacter pylori eradication therapy.
Recommendations by the 2nd Spanish Consensus Conference.
Rev Esp Enferm Dig 97(5):348–374
Monteiro L, de Mascarel A, Sarrasqueta AM, Bergey B, Barberis C,
Talby P, Roux D, Shouler L, Goldfain D, Lamouliatte H, Megraud
F (2001a) Diagnosis of Helicobacter pylori infection: noninvasive
methods compared to invasive methods and evaluation of two new
tests. Am J Gastroenterol 96(2):353–358. doi:10.1111/j.1572-0241.
2001.03518.x
Monteiro L, Gras N, Vidal R, Cabrita J, Megraud F (2001b) Detection of
Helicobacter pylori DNA in human feces by PCR: DNA stability
and removal of inhibitors. J Microbiol Methods 45(2):89–94
Morozov VN, Groves S, Turell MJ, Bailey C (2007) Three minutes-long
electrophoretically assisted zeptomolar microfluidic immunoassay
with magnetic-beads detection. J Am Chem Soc 129(42):12628–
12629. doi:10.1021/ja075069m
Noordin R, Santhanam A, Khalilpour A, Wei lee C, Osman S (2013)
Helicobacter pylori proteins for diagnostic kit and vaccine.
WO2013019098A1
Park J-W, Song J-Y, Lee S-G, Jun J-S, Park J-U, Chung M-J, Ju J-S,
Nizamutdinov D, Chang M-W, Youn H-S, Kang H-L, Baik S-C,
Lee W-K, Cho M-J, Rhee K-H (2006) Quantitative analysis of rep-
resentative proteome components and clustering of Helicobacter
pylori clinical strains. Helicobacter 11(6):533–543
Peek RM Jr, Fiske C, Wilson KT (2010) Role of innate immunity in
Helicobacter pylori-induced gastric malignancy. Physiol Rev
90(3):831–858. doi:10.1152/physrev.00039.2009
Pelerito A, Oleastro M, Lopes AI, Ramalho P, Cabral J, Monteiro L
(2006) Evaluation of rapid test Assure Helicobacter pylori for
Appl Microbiol Biotechnol (2016) 100:4723–4734 4733
diagnosis of H. pylori in pediatric population. J Microbiol Methods
66(2):331–335. doi:10.1016/j.mimet.2005.12.013
Pereira SV, Messina GA, Raba J (2010) Integrated microfluidic magnetic
immunosensor for quantification of human serum IgG antibodies to
Helicobacter pylori. J Chromatogr B 878(2):253–257
Perez-Perez GI (2000) Accurate diagnosis of Helicobacter pylori.
Culture, including transport. Gastroenterol Clin N Am 29(4):
879–884
Portal-Celhay C, Perez-Perez GI (2006) Immune responses to
Helicobacter pylori colonization: mechanisms and clinical
outcomes. Clin Sci (Lond) 110(3):305–314
Rahim ABA (2004) Study on risk factors of H. pylori infection and its
prevalence among, adult indigenous Orang Asli population in Gua
Musang District of North Eastern area of Malaysia. Malaysian J
Med Sci 11(1):100–101
Riahi R, Tamayol A, Shaegh SAM, Ghaemmaghami AM, Dokmeci MR,
Khademshosseini A (2015) Microfluidics for advanced drug deliv-
ery systems. Current Opin Chem Eng 7:101–112
Robinson K, Argent RH, Atherton JC (2007) The inflammatory and
immune response to Helicobacter pylori infection. Best Pract Res
Clin Gastroenterol 21(2):237–259. doi:10.1016/j.bpg.2007.01.001
Rosenstock S, Jorgensen T, Andersen L, Bonnevie O (2000)
Seroconversion and seroreversion in IgG antibodies to
Helicobacter pylori: a serology based prospective cohort study. J
Epidemiol Community Health 54(6):444–450
Safavieh R, Juncker D (2013) Capillarics: pre-programmed, self-powered
microfluidic circuits built from capillary elements. Lab Chip 13(21):
4180–4189
Safavieh R, Tamayol A, Juncker D (2015) Serpentine and leading-edge
capillary pumps for microfluidic capillary systems. Microfluid
Nanofluid 18(3):357–366
Sasidharan S, Uyub AM (2009) Antibody response to Helicobacter
pylori excretory antigen and the cross reaction study. J
Immunoassay Immunochem 30(1):70–81. doi:10.1080/
15321810802569477
Schumann C, Triantafilou K, Rasche FM, Moricke A, Vogt K,
Triantafilou M, Hahn P, Schneider EM, Lepper PM (2006) Serum
antibody positivity for distinct Helicobacter pylori antigens in be-
nign and malignant gastroduodenal disease. Int J Med Microbiol
296(4–5):223–228. doi:10.1016/j.ijmm.2006.02.009
Simor AE, Lin E, Saibil F, Cohen L, Louie M, Pearen S, Donhoffer HA
(1996) Evaluation of enzyme immunoassay for detection of salivary
antibody to Helicobacter pylori. J Clin Microbiol 34(3):550–553
Sugimoto M,Wu JY, Abudayyeh S, Hoffman J, Brahem H, Al-Khatib K,
Yamaoka Y, Graham DY (2009) Unreliability of results of PCR
detection of Helicobacter pylori in clinical or environmental sam-
ples. J Clin Microbiol 47(3):738–742. doi:10.1128/JCM.01563-08
Tiwari SK, Khan AA, Ahmed KS, Ahmed I, Kauser F, Hussain MA, Ali
SM, Alvi A, Habeeb A, Abid Z, Ahmed N, Habibullah CM (2005)
Rapid diagnosis of Helicobacter pylori infection in dyspeptic pa-
tients using salivary secretion: a non-invasive approach. SingapMed
J 46(5):224–228
Vaira D, Vakil N (2001) Blood, urine, stool, breath, money, and
Helicobacter pylori. Gut 48(3):287–289
Wadstrom T, Bolin I, Fandriks L, Gad A, Carling L (1994) Diagnosis of
Helicobacter pylori infection. Lakartidningen 91(19):1926–1927
Wang S, Zhang W-M, Reineks E (2013) Breath tests for detection of
Helicobacter pylori and Aspergillus fumigatus. In: Stratton CW
(ed) Tang Y-W. Advanced Techniques in Diagnostic Microbiology,
Springer US, pp. 13–30
Yan J, Mao YF, Shao ZX (2005) Frequencies of the expression of main
protein antigens fromHelicobacter pylori isolates and production of
specific serum antibodies in infected patients. World J Gastroenterol
11(3):421–425
Yang HR, Seo JK (2008) Helicobacter pylori stool antigen (HpSA) tests
in children before and after eradication therapy: comparison of rapid
immunochromatographic assay and HpSA ELISA. Dig Dis Sci
53(8):2053–2058
Yousfi MM, El-Zimaity HM, Cole RA, Genta RM, Graham DY (1996)
Detection ofHelicobacter pylori by rapid urease tests: is biopsy size
a critical variable? Gastrointest Endosc 43(3):222–224
el-Zaatari FA, Oweis SM, Graham DY (1997) Uses and cautions for use
of polymerase chain reaction for detection of Helicobacter pylori.
Dig Dis Sci 42(10):2116–2119
Zheng J, Xiao-Hong T, Huang A-L, Wang P-L (2002) A study of recom-
binant protective H. pylori antigens. World J Gastroenterol 8(2):
308–311
Zuniga-Noriega JR, Bosques-Padilla FJ, Perez-Perez GI, Tijerina-
Menchaca R, Flores-Gutierrez JP, Maldonado Garza HJ, Garza-
Gonzalez E (2006) Diagnostic utility of invasive tests and serology
for the diagnosis ofHelicobacter pylori infection in different clinical
presentations. ArchMed Res 37(1):123–128. doi:10.1016/j.arcmed.
2005.04.020
4734 Appl Microbiol Biotechnol (2016) 100:4723–4734
